ADT 010
Alternative Names: ADT-010Latest Information Update: 29 May 2022
Price :
$50 *
At a glance
- Originator Adaptate Biotherapeutics
- Developer Takeda
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 26 May 2022 Preclinical trials in Cancer in United Kingdom (Parenteral) (Adaptate Biotherapeutics pipeline, May 2022)
- 08 Apr 2022 Pharmacodynamics data from a preclinical study in Cancer presented at the 113th annual meeting of the American Association for Cancer Research (AACR-2022)
- 08 Apr 2022 Adaptate Biotherapeutics plans a clinical trial for Solid tumors in United Kingdom